Loratadine to prevent bone pain after stem cell transplant treatment
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Pain clinical trials.
This trial tests loratadine (an allergy medicine) to see if it can prevent bone pain caused by a growth-factor injection used during lymphoma or multiple myeloma treatment. It may help reduce pain around the time you get that injection and your upcoming stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lymphoma or multiple myeloma (confirmed by lab testing).
- Your next treatment plan is an autologous stem cell transplant (using your own stem cells).
- You are 18 years or older.
- Your general functioning level is good enough (ECOG 0 to 2).
- You’re able to follow the study schedule and visits, and you’re expected to live at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial studies whether loratadine (an allergy medicine) can reduce bone pain caused by G-CSF, which is used to help your body collect stem cells. If you have multiple myeloma and are preparing for stem cell mobilization, this may make treatment-related bone pain more tolerable.
This study tests whether taking a combination of two natural compounds (diosmin and hesperidin) similar to those from citrus fruits, or the allergy medicine loratadine, can prevent or reduce bone pain caused by G-CSF injections—a common treatment to boost white blood cells in people with blood cancers.
This trial tests if a bone-strengthening medicine called zoledronate can help prevent bone problems in children and teens who have had a stem cell transplant. It may be an option for patients with low bone density or those who develop graft-versus-host disease after transplant.
This trial tests a new drug called axatilimab, given alongside standard care, to help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for people who are planning a first transplant from a matched donor.
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Hear when a new Stem Cell Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.